CNS Drugs
Title Abbreviation
CNS Drugs
Electronic ISSN
1179-1934
Readership
Academicians, Anesthesiologists, Caregivers, Clinicians, Geriatricians, Neurologists, Pain Specialists, Patients, Pediatricians, Pharmacologists, Physiatrists, Psychiatrists, Researchers, Substance Abuse Administrators
Scope
CNS Drugs promotes rational pharmacotherapy within the disciplines of clinical psychiatry and neurology. The Journal includes:
Overviews of contentious or emerging issues.
Comprehensive narrative reviews that provide an authoritative source of information on pharmacological approaches to managing neurological and psychiatric illnesses.
Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in neurology and psychiatry.
Original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies.
Sponsoring Association(s)
No associations affiliated with this journal
Publisher Name
Adis, part of Springer Nature
Impact Factor
JCR Categories/Rank
Electronic Circulation
Frequency
Journal Contact
Author Submission Guidelines